NCT02384577View on ClinicalTrials.gov

Study to Evaluate Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and COPD Treatment

CompletedOBSERVATIONAL
Enrollment

4,034

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

September 30, 2016

Conditions
Patient Satisfaction
Interventions
DRUG

Budesonide, Formoterol Fumarate Dihydrate

Trial Locations (1)

Unknown

Teva Investigational Sites, Berlin

All Listed Sponsors
lead

Teva Pharma GmbH

INDUSTRY

NCT02384577 - Study to Evaluate Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and COPD Treatment | Biotech Hunter | Biotech Hunter